FDA Panel Recommends More Hydrocodone Combo Restrictions

Washington Drug Letter
A A
An FDA advisory panel voted 19–10 to recommend up-scheduling hydrocodone combination products to schedule II controlled substances on Jan. 25, a move that would bring tighter restrictions on the opioid painkillers.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00